Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.
Treatment Controversies in Meniere’s Disease Shashidhar S. Reddy, MD, MPH Shawn D. Newlands, MD, PhD UTMB Otolaryngology  ...
Outline <ul><li>History and Meniere’s </li></ul><ul><li>Definition of Meniere’s </li></ul><ul><li>Physiology, Pathophysiol...
History of Meniere’s <ul><li>1861 – Prosper Meniere describes classic symptoms and attributes to labyrinth </li></ul><ul><...
Definition of Meniere’s Disease <ul><li>AAO-HNS Committee on Hearing and Equilibrium revised definition in 1995   </li></u...
Definition of Meniere’s <ul><li>Staging of Hearing Loss in Definite/Certain Meniere’s: </li></ul>Committee on Hearing and ...
Definition of Meniere’s <ul><li>Functional Level Scale </li></ul><ul><ul><li>Regarding my current state of overall functio...
Definition of Meniere’s <ul><li>Reporting Results of Treatment: </li></ul><ul><ul><li>Divide frequency of spells 18-24mont...
Physiology <ul><li>Perilymph – Similar in composition to CSF </li></ul><ul><ul><li>High Na+, Low K+ </li></ul></ul><ul><li...
Physiology <ul><li>Production and flow of Endolymph - Theories </li></ul><ul><ul><li>Longitudinal – produced in membranous...
Pathophysiology <ul><li>Endolymphatic hydrops leads to distortion of membranous labyrinth </li></ul>
Pathophysiology <ul><li>Build up in pressure may lead to micro-ruptures of membranous labyrinth (Minor  et al ) </li></ul>...
Pathophysiology <ul><li>What causes hydrops? </li></ul><ul><ul><li>Obstruction of endolymphatic duct/sac </li></ul></ul><u...
Pathophysiology <ul><li>Hydrops role in causation of Meniere’s is not entirely clear </li></ul><ul><ul><li>Rauche  et al  ...
Pathophysiology <ul><li>Silverstein  et al  found that in pts. who refused surgical tx., there was resolution of vestibula...
Medical Management <ul><li>Acute Therapy </li></ul><ul><li>Maintenance Therapy </li></ul>
Medical Management <ul><li>Acute Therapy </li></ul><ul><ul><li>Relatively non-controversial </li></ul></ul>Brookes, G.B. T...
Medical Management <ul><li>Maintenance Therapy </li></ul><ul><ul><li>No conclusive studies show efficacy of drugs intended...
Medical Management <ul><li>Diuretics and Salt restriction </li></ul><ul><ul><li>? Alter fluid balance in inner ear leading...
Medical Management <ul><li>Diuretics and Salt Restriction </li></ul><ul><ul><li>Ruckenstein  et al  evaluated data from tw...
Medical Management <ul><li>Osmotic Diuretics (Urea, Glycerol) </li></ul><ul><ul><li>Have been consistently shown to reduce...
Medical Management <ul><li>Vasodilators </li></ul><ul><ul><li>Purported to work by decreasing ischemia in the inner ear an...
Medical Management <ul><li>Immunologic Management </li></ul><ul><ul><li>Systemic steroids and intratympanic dexamethasone ...
Mechanical Management <ul><li>Transtympanic “Micropressure” Treatment </li></ul><ul><ul><li>Meniett Device (Xomed) – FDA a...
Mechanical Management <ul><li>Gates  et al  2004  </li></ul><ul><ul><li>Prospective, randomized, placebo control trial of ...
Intratympanic Therapy <ul><li>Goal is to maximize local effects in inner ear while minimizing systemic effects </li></ul><...
Intratympanic Therapy <ul><li>Fowler in 1948, and later Schuknecht established role of systemic streptomycin for bilateral...
Intratympanic Gentamicin <ul><li>Preferred because of Gentamicin’s vestibuloselectivity </li></ul><ul><li>Side effects can...
Intratympanic Gentamicin <ul><li>Titration Therapy </li></ul><ul><ul><li>Martin and Perez 2003 (prospective study, n=71) <...
Intratympanic Gentamicin <ul><li>Ablation via Multiple Daily Dosing </li></ul><ul><ul><li>Jackson and Silverstein – Study ...
Intratympanic Gentamicin <ul><li>Low dose therapy </li></ul><ul><ul><li>Harner  et al  2001 – retrospective study of 51 pa...
Intratympanic Gentamicin <ul><li>Other methods of delivery </li></ul><ul><ul><li>Weekly administration </li></ul></ul><ul>...
Intratympanic Gentamicin <ul><li>Chia  et al  performed a meta-analysis of different modalities of application in 2004 </l...
Intratympanic Gentamicin <ul><li>Hearing loss was greatest for multiple daily dosing </li></ul><ul><li>Hearing loss was le...
Endolymphatic Sac Surgery <ul><li>Purported to address the site of obstruction causing hydrops </li></ul><ul><ul><li>4 typ...
Endolymphatic Sac Surgery Coker, Newton J.  et al   Atlas of Otologic Surgery .  W.B. Saunders 2001
Endolymphatic Sac Surgery <ul><li>Jens Thomsen  et al  1981 </li></ul><ul><ul><li>Double-blinded placebo-control study wit...
Vestibular Nerve Section <ul><li>Can achieve vestibular suppression without any effect on hearing </li></ul><ul><li>Single...
Vestibular Nerve Section Coker, Newton J.  et al   Atlas of Otologic Surgery .  W.B. Saunders 2001
Vestibular Nerve Section <ul><li>Hillman  et al  2004 retrospectively compared v. nerve section to intratymp. Gent. </li><...
Vestibular Nerve Section <ul><li>Hillman  et al  continued </li></ul>
Vestibular Nerve Section <ul><li>Hillman  et al  continued </li></ul><ul><ul><li>No incidence of wound infection or mening...
Other Ablative Surgeries <ul><li>Labyrinthectomy </li></ul><ul><ul><li>Useful in patients with no serviceable hearing and ...
Conclusions <ul><li>Therapies that definitely reduce vertigo in Meniere’s Disease: </li></ul><ul><ul><li>Vestibular suppre...
Próximo SlideShare
Cargando en…5
×

de

Menieres slides-050518 Slide 1 Menieres slides-050518 Slide 2 Menieres slides-050518 Slide 3 Menieres slides-050518 Slide 4 Menieres slides-050518 Slide 5 Menieres slides-050518 Slide 6 Menieres slides-050518 Slide 7 Menieres slides-050518 Slide 8 Menieres slides-050518 Slide 9 Menieres slides-050518 Slide 10 Menieres slides-050518 Slide 11 Menieres slides-050518 Slide 12 Menieres slides-050518 Slide 13 Menieres slides-050518 Slide 14 Menieres slides-050518 Slide 15 Menieres slides-050518 Slide 16 Menieres slides-050518 Slide 17 Menieres slides-050518 Slide 18 Menieres slides-050518 Slide 19 Menieres slides-050518 Slide 20 Menieres slides-050518 Slide 21 Menieres slides-050518 Slide 22 Menieres slides-050518 Slide 23 Menieres slides-050518 Slide 24 Menieres slides-050518 Slide 25 Menieres slides-050518 Slide 26 Menieres slides-050518 Slide 27 Menieres slides-050518 Slide 28 Menieres slides-050518 Slide 29 Menieres slides-050518 Slide 30 Menieres slides-050518 Slide 31 Menieres slides-050518 Slide 32 Menieres slides-050518 Slide 33 Menieres slides-050518 Slide 34 Menieres slides-050518 Slide 35 Menieres slides-050518 Slide 36 Menieres slides-050518 Slide 37 Menieres slides-050518 Slide 38 Menieres slides-050518 Slide 39 Menieres slides-050518 Slide 40 Menieres slides-050518 Slide 41 Menieres slides-050518 Slide 42 Menieres slides-050518 Slide 43

Menieres slides-050518

  1. 1. Treatment Controversies in Meniere’s Disease Shashidhar S. Reddy, MD, MPH Shawn D. Newlands, MD, PhD UTMB Otolaryngology Grand Rounds May 18, 2005
  2. 2. Outline <ul><li>History and Meniere’s </li></ul><ul><li>Definition of Meniere’s </li></ul><ul><li>Physiology, Pathophysiology of Meniere’s </li></ul><ul><li>Medical Management of Meniere’s </li></ul><ul><li>Meniet Device </li></ul><ul><li>Intratympanic Gentamicin </li></ul><ul><li>Endolymphatic Sac Surgery </li></ul><ul><li>Vestibular Nerve Section </li></ul><ul><li>Conclusions </li></ul>
  3. 3. History of Meniere’s <ul><li>1861 – Prosper Meniere describes classic symptoms and attributes to labyrinth </li></ul><ul><li>1871 – Knappin theorizes dilatation of membranous Labyrinth </li></ul><ul><li>1938 – Hallpike and Portman confirm endolymphatic hydrops via temporal bone histology </li></ul><ul><li>1995 – Latest revision of AAOHNS definition </li></ul>
  4. 4. Definition of Meniere’s Disease <ul><li>AAO-HNS Committee on Hearing and Equilibrium revised definition in 1995 </li></ul><ul><ul><li>Possible Meniere's disease </li></ul></ul><ul><ul><ul><li>Episodic vertigo of the Meniere's type without documented hearing loss, or </li></ul></ul></ul><ul><ul><ul><li>Sensorineural hearing loss, fluctuating or fixed, with dysequilibrium but without definitive episodes </li></ul></ul></ul><ul><ul><ul><li>Other causes excluded </li></ul></ul></ul><ul><ul><li>Probable Meniere's disease </li></ul></ul><ul><ul><ul><li>One definitive episode of vertigo </li></ul></ul></ul><ul><ul><ul><li>Audiometrically documented hearing loss on at least one occasion </li></ul></ul></ul><ul><ul><ul><li>Tinnitus or aural fullness in the treated ear </li></ul></ul></ul><ul><ul><ul><li>Other causes excluded  </li></ul></ul></ul><ul><ul><li>Definite Meniere's disease </li></ul></ul><ul><ul><ul><li>Two or more definitive spontaneous episodes of vertigo 20 minutes or longer </li></ul></ul></ul><ul><ul><ul><li>Audiometrically documented hearing loss on at least one occasion </li></ul></ul></ul><ul><ul><ul><li>Tinnitus or aural fullness in the treated ear </li></ul></ul></ul><ul><ul><ul><li>Other cases excluded  </li></ul></ul></ul><ul><ul><li>Certain Meniere's disease </li></ul></ul><ul><ul><ul><li>Definite Meniere's disease, plus histopathologic confirmation </li></ul></ul></ul>Committee on Hearing and Equilibrium Guidelines for Diagnoses and Evaluation of Therapy in Meniere’s Disease, AAOHNS Board of Directors March 1994
  5. 5. Definition of Meniere’s <ul><li>Staging of Hearing Loss in Definite/Certain Meniere’s: </li></ul>Committee on Hearing and Equilibrium Guidelines for Diagnoses and Evaluation of Therapy in Meniere’s Disease, AAOHNS Board of Directors March 1994 >70 4 41-70 3 26-40 2 <=25 1 Four Tone Average dB Stage
  6. 6. Definition of Meniere’s <ul><li>Functional Level Scale </li></ul><ul><ul><li>Regarding my current state of overall function, not just during attacks (check the ONE that best applies): </li></ul></ul><ul><ul><li>1. My dizziness has no effect on my activities at all. </li></ul></ul><ul><ul><li>2. When I am dizzy I have to stop what I am doing for a while, but it soon passes and I can resume activities. I continue to work, drive, and engage in any activity I choose without restriction. I have not changed any plans or activities to accommodate my dizziness. </li></ul></ul><ul><ul><li>3. When I am dizzy, I have to stop what I am doing for a while, but it does pass and I can resume activities. I continue to work, drive, and engage in most activities I choose, but I have had to change some plans and make some allowance for my dizziness. </li></ul></ul><ul><ul><li>4. I am able to work, drive, travel, take care of a family, or engage in most essential activities, but I must exert a great deal of effort to do so. I must constantly make adjustments in my activities and budge my energies. I am barely making it. </li></ul></ul><ul><ul><li>5. I am unable to work, drive, or take care of a family. I am unable to do most of the active things that I used to. Even essential activities must be limited. I am disabled. </li></ul></ul><ul><ul><li>6. I have been disabled for 1 year or longer and/or I receive compensation (money) because of my dizziness or balance problem. </li></ul></ul>Committee on Hearing and Equilibrium Guidelines for Diagnoses and Evaluation of Therapy in Meniere’s Disease, AAOHNS Board of Directors March 1994
  7. 7. Definition of Meniere’s <ul><li>Reporting Results of Treatment: </li></ul><ul><ul><li>Divide frequency of spells 18-24months by number 6months prior to tx and multiplyx100 </li></ul></ul>Committee on Hearing and Equilibrium Guidelines for Diagnoses and Evaluation of Therapy in Meniere’s Disease, AAOHNS Board of Directors March 1994 E >120 F Secondary Treatment D 81-120 C 41 to 80 B 1 to 40 A 0 Class Numerical Value
  8. 8. Physiology <ul><li>Perilymph – Similar in composition to CSF </li></ul><ul><ul><li>High Na+, Low K+ </li></ul></ul><ul><li>Endolymph – Similar in compostion to ICF </li></ul><ul><ul><li>Low Na+ High K+ </li></ul></ul><ul><ul><li>Believed to be produced in Stria Vascularis </li></ul></ul><ul><li>Membranous Labyrinth separates the two </li></ul><ul><ul><li>Difference of 80mV in charge </li></ul></ul><ul><ul><li>No difference in pressure </li></ul></ul>
  9. 9. Physiology <ul><li>Production and flow of Endolymph - Theories </li></ul><ul><ul><li>Longitudinal – produced in membranous labyrinth, flows to endolymphatic sac, then to dural venous sinuses </li></ul></ul><ul><ul><li>Diffuse – produced and absorbed along the membranous labyrinth </li></ul></ul><ul><ul><li>Periodic Flow – endolymph flows only with changes in volume or pressure </li></ul></ul>Andrews, JC, Intralabyrinthine fluid dynamics: Meniere disease 12(5) Oct 2004 pp408-412
  10. 10. Pathophysiology <ul><li>Endolymphatic hydrops leads to distortion of membranous labyrinth </li></ul>
  11. 11. Pathophysiology <ul><li>Build up in pressure may lead to micro-ruptures of membranous labyrinth (Minor et al ) </li></ul><ul><ul><li>Ruptures are confirmed by various histologic studies </li></ul></ul><ul><ul><li>May responsible for episodic nature of attacks </li></ul></ul><ul><ul><li>Healing of ruptures may account for return of hearing </li></ul></ul>Review Article: Minor, Lloyd et al , Meniere’s Disease, Current Opinion in Neurology 17(1) Feb2004
  12. 12. Pathophysiology <ul><li>What causes hydrops? </li></ul><ul><ul><li>Obstruction of endolymphatic duct/sac </li></ul></ul><ul><ul><ul><li>Obstruction of endolymphatic sac in does not cause hydrops in all animals and causes vertigo in few </li></ul></ul></ul><ul><ul><li>Alteration of absorption of endolymph </li></ul></ul><ul><ul><li>Immunologic insult to inner ear </li></ul></ul><ul><ul><ul><li>Elevated levels of IG’s in endolymph </li></ul></ul></ul>
  13. 13. Pathophysiology <ul><li>Hydrops role in causation of Meniere’s is not entirely clear </li></ul><ul><ul><li>Rauche et al 1998 – Study of 19 temporal bone histologies with hydrops- </li></ul></ul><ul><ul><ul><li>13/19 patients with hydrops by histology showed Meniere’s symptoms by chart review </li></ul></ul></ul><ul><ul><ul><li>6/19 showed no Meniere’s symptoms by chart review </li></ul></ul></ul>Rauch SD, et al Meniere’s syndrome and endolymphatic hydrops: double blind temporal bone study. Ann Otol Rhinol Laryngol 1989; 98:873-883
  14. 14. Pathophysiology <ul><li>Silverstein et al found that in pts. who refused surgical tx., there was resolution of vestibular symptoms </li></ul><ul><ul><li>57-60% of patients in 2 years </li></ul></ul><ul><ul><li>71% at eight years. </li></ul></ul><ul><ul><li>Long term PTA in affected ear is 50dB </li></ul></ul><ul><ul><li>Speech discrimination is 53% </li></ul></ul><ul><ul><li>Caloric response reduction is 50% </li></ul></ul>Silverstein H., Smouha E. & Jones R. (1989) Natural history vs surgery for Ménière's disease. Otolaryngol. Head Neck Surg. 100, 6-16
  15. 15. Medical Management <ul><li>Acute Therapy </li></ul><ul><li>Maintenance Therapy </li></ul>
  16. 16. Medical Management <ul><li>Acute Therapy </li></ul><ul><ul><li>Relatively non-controversial </li></ul></ul>Brookes, G.B. The pharmacological treatment of Meniere’s disease. Clinical Otolaryngology 21(1) Feb1996, pp3-11
  17. 17. Medical Management <ul><li>Maintenance Therapy </li></ul><ul><ul><li>No conclusive studies show efficacy of drugs intended to alter disease course of Meniere’s </li></ul></ul>
  18. 18. Medical Management <ul><li>Diuretics and Salt restriction </li></ul><ul><ul><li>? Alter fluid balance in inner ear leading to depletion of endolymph </li></ul></ul><ul><ul><li>Shinkawa/Kimura unable to demonstrate beneficial effect on hydrops in animal model </li></ul></ul>Shinkawa H. & Kimura R.S. (1986) Effect of diuretics on endolymphatic hydrops. Acta. Otolaryngol. (Stockh.)101, 43-52
  19. 19. Medical Management <ul><li>Diuretics and Salt Restriction </li></ul><ul><ul><li>Ruckenstein et al evaluated data from two double blind studies by Klockhoff and Lindblom on HCTZ vs. Placebo and showed no difference in Diuretics vs. placebo </li></ul></ul>Ruckenstein M.J., Rutka J.A. & Hawke M. (1991) The treatment of Meniere's disease: Torok revisited. Laryngoscope101, 211-218
  20. 20. Medical Management <ul><li>Osmotic Diuretics (Urea, Glycerol) </li></ul><ul><ul><li>Have been consistently shown to reduce symptoms in a proportion of patients, but the effects only last for a few hours </li></ul></ul><ul><ul><li>Objective data includes alteration of the SP:AP ratio on Electrocochleography </li></ul></ul><ul><li>Acetazolamide – was actually shown to increase hydrops and hearing loss when given IV and had no benefit p.o. </li></ul>
  21. 21. Medical Management <ul><li>Vasodilators </li></ul><ul><ul><li>Purported to work by decreasing ischemia in the inner ear and allowing better metabolism of endolymph </li></ul></ul><ul><ul><li>Betahistine is a popular choice, with several studies showing decreased vertigo with use </li></ul></ul><ul><ul><ul><li>Cochrane Database Review (2004) – Only one Grade B study and four Grade C studies, none of which produced convincing evidence for use. </li></ul></ul></ul>James, AL, et al . Betahistine for Meniere’s disease or syndrome. Cochrane Database of Systematic Reviews (2) 2005
  22. 22. Medical Management <ul><li>Immunologic Management </li></ul><ul><ul><li>Systemic steroids and intratympanic dexamethasone have been studied and showed no conclusive benefit. </li></ul></ul><ul><ul><li>Double-blinded prospective crossover study by Silverstein et al showed no difference from placebo with intratympanic dexamethasone injections </li></ul></ul>Silverstein, Herbert et al Dexamethasone inner ear perfusion for the treatment of meniere’s disease: a prospective, randomized, double-blind, crossover trial. American Journal of Otology. 1998. 19:196-201
  23. 23. Mechanical Management <ul><li>Transtympanic “Micropressure” Treatment </li></ul><ul><ul><li>Meniett Device (Xomed) – FDA approved in 1999 as a class II device </li></ul></ul><ul><ul><li>Advocates present no strong case for why the device should work </li></ul></ul><ul><ul><li>Portably, low intensity alternating pressure generator </li></ul></ul>
  24. 24. Mechanical Management <ul><li>Gates et al 2004 </li></ul><ul><ul><li>Prospective, randomized, placebo control trial of Meniett device </li></ul></ul>Gates GA. Green JD Jr. Tucci DL. Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Meniere's disease. Archives of Otolaryngology -- Head & Neck Surgery. 130(6):718-25, 2004 Jun. Did not use standardized vertigo assesment Did not comment on severity of vertigo Did not give good data on objective testing
  25. 25. Intratympanic Therapy <ul><li>Goal is to maximize local effects in inner ear while minimizing systemic effects </li></ul><ul><li>Round window is point of diffusion to inner ear </li></ul><ul><li>Intratympanic dexamethasone already discussed </li></ul><ul><li>Aminoglycoside Antibiotics: affect hair cells of crista, ampulla, and cochlea </li></ul>
  26. 26. Intratympanic Therapy <ul><li>Fowler in 1948, and later Schuknecht established role of systemic streptomycin for bilateral disease (2gIVPB qd until vestibular symptoms were noted) </li></ul><ul><li>Hearing loss and oscillopsia were a problem with this therapy, though reducing dosage seemed to help </li></ul>
  27. 27. Intratympanic Gentamicin <ul><li>Preferred because of Gentamicin’s vestibuloselectivity </li></ul><ul><li>Side effects can include temporary imbalance or nystagmus </li></ul><ul><li>Hearing loss </li></ul><ul><li>Many methods of delivery exist </li></ul>
  28. 28. Intratympanic Gentamicin <ul><li>Titration Therapy </li></ul><ul><ul><li>Martin and Perez 2003 (prospective study, n=71) </li></ul></ul><ul><ul><ul><li>Serial daily injections of buffered (pH 6.4) 26.7mg/cc gentamicin solution via 27 gauge needle into middle ear </li></ul></ul></ul><ul><ul><ul><li>Injections repeated until vestibular symptoms developed (spontaneous or evoked nystagmus) </li></ul></ul></ul><ul><ul><ul><li>At 2 years, 69% had Class A vertigo control, 14.1% had Class B </li></ul></ul></ul><ul><ul><ul><li>32.4% had hearing loss </li></ul></ul></ul>Martin E, Perez N: Hearing loss after intratympanic gentamicin therapy for unilateral Meniere’s Disease. Otol Neurotol 2003, 24:800-806
  29. 29. Intratympanic Gentamicin <ul><li>Ablation via Multiple Daily Dosing </li></ul><ul><ul><li>Jackson and Silverstein – Study on 92 patients who underwent myringotomy and wick placement through to round window niche. </li></ul></ul><ul><ul><ul><li>Pts. self-administered gentamicin drops TID until 100% reduction on ENG of vestibular response </li></ul></ul></ul><ul><ul><ul><li>85% relief of vertigo, 67% improvement in aural pressure </li></ul></ul></ul><ul><ul><ul><li>36% hearing loss </li></ul></ul></ul>Jackson, LE; Silverstein, H: Chemical perfusion of the inner ear. Otolaryngol Clin North Am 2002, 35:639-653
  30. 30. Intratympanic Gentamicin <ul><li>Low dose therapy </li></ul><ul><ul><li>Harner et al 2001 – retrospective study of 51 patients who received 1 dose of 40mg/mL injection and were re-evaluated in 1 month and given another if needed </li></ul></ul><ul><ul><li>At 2 years, 86% had vertigo class A or B </li></ul></ul><ul><ul><li>He reported minimal change in PTA but drop in SRT’s </li></ul></ul><ul><ul><li>Claimed better hearing preservation with this </li></ul></ul>Harner, Stephen et al : Long-term follow-up of transtympanic gentamicin for Meniere’s Syndrome. Otology & Neurotol 22:210-214, 2001
  31. 31. Intratympanic Gentamicin <ul><li>Other methods of delivery </li></ul><ul><ul><li>Weekly administration </li></ul></ul><ul><ul><ul><li>Single dose of gentamicin once a week for four treatments </li></ul></ul></ul><ul><ul><li>Continuous administration </li></ul></ul><ul><ul><ul><li>Microcatheter delivery of gentamicin using a continuous perfusion method </li></ul></ul></ul><ul><ul><ul><li>Results in extremely variable amount of gentamicin delivery </li></ul></ul></ul><ul><ul><ul><li>Better perfusion techniques may be needed </li></ul></ul></ul>
  32. 32. Intratympanic Gentamicin <ul><li>Chia et al performed a meta-analysis of different modalities of application in 2004 </li></ul>Chia, Stanley H, et al Intratympanic Gentamicin Therapy for Meniere’s Disease: a Meta-Analysis. Otology&Neurotol 25(4) July 2004 pp 544-552 Class A or B Vertigo Control
  33. 33. Intratympanic Gentamicin <ul><li>Hearing loss was greatest for multiple daily dosing </li></ul><ul><li>Hearing loss was least for titration therapy </li></ul><ul><li>Hearing loss was not lower than average for low-dose therapy </li></ul>
  34. 34. Endolymphatic Sac Surgery <ul><li>Purported to address the site of obstruction causing hydrops </li></ul><ul><ul><li>4 types: </li></ul></ul><ul><ul><ul><li>Decompression – removal of bone around the sac </li></ul></ul></ul><ul><ul><ul><li>Shunting – placement of synthetic shunt to drain endolymph into mastoid </li></ul></ul></ul><ul><ul><ul><li>Drainage – incision of the sac to allow drainage </li></ul></ul></ul><ul><ul><ul><li>Removal of sac – to address the possibility that the sac may actually play a role in endolymph production </li></ul></ul></ul>
  35. 35. Endolymphatic Sac Surgery Coker, Newton J. et al Atlas of Otologic Surgery . W.B. Saunders 2001
  36. 36. Endolymphatic Sac Surgery <ul><li>Jens Thomsen et al 1981 </li></ul><ul><ul><li>Double-blinded placebo-control study with sham surgery (cortical mastoidectomy) vs endolymphatic shunt placement in 30 patients </li></ul></ul><ul><ul><li>No difference in any outcome between sham surgery and endolymphatic sac shunt group </li></ul></ul>Thomsen, Jen et al . Placebo Effect in Surgery for Meniere’s Disease. Arch Otolaryngol – Vol 107, May 1981, pp271-277
  37. 37. Vestibular Nerve Section <ul><li>Can achieve vestibular suppression without any effect on hearing </li></ul><ul><li>Single step procedure </li></ul><ul><li>Can have intraoperative complications of damage to facial nerve, cochlear nerve, or CSF leak (rate of CSF leak is about 13%) </li></ul><ul><li>Approaches: Middle Fossa, Retrolabyrinthine/Retrosigmoid </li></ul>
  38. 38. Vestibular Nerve Section Coker, Newton J. et al Atlas of Otologic Surgery . W.B. Saunders 2001
  39. 39. Vestibular Nerve Section <ul><li>Hillman et al 2004 retrospectively compared v. nerve section to intratymp. Gent. </li></ul><ul><ul><li>Performed via combined mastoidectomy/retrosig approach </li></ul></ul>Hillman, Todd A, et al. Vestibular Nerve Section Versus Intratympanic Gentamicin for Meniere’s Disease. Laryngoscope 114:pp 216-224
  40. 40. Vestibular Nerve Section <ul><li>Hillman et al continued </li></ul>
  41. 41. Vestibular Nerve Section <ul><li>Hillman et al continued </li></ul><ul><ul><li>No incidence of wound infection or meningitis in this group </li></ul></ul><ul><ul><li>12.6% incidence of CSF leak requiring LP and extended hospitalization </li></ul></ul><ul><ul><li>Rates of disequilibrium were similar but persisted longer in the nerve section group </li></ul></ul>
  42. 42. Other Ablative Surgeries <ul><li>Labyrinthectomy </li></ul><ul><ul><li>Useful in patients with no serviceable hearing and those who cannot tolerate intracranial procedure </li></ul></ul><ul><ul><li>Similar in efficacy to vestibular nerve section </li></ul></ul>
  43. 43. Conclusions <ul><li>Therapies that definitely reduce vertigo in Meniere’s Disease: </li></ul><ul><ul><li>Vestibular suppressant medications </li></ul></ul><ul><ul><li>Intratympanic Gentamicin (especially when titrated) </li></ul></ul><ul><ul><li>Vestibular Nerve Section </li></ul></ul><ul><ul><li>Labyrinthectomy </li></ul></ul><ul><li>Other therapies discussed are unproven or controversial </li></ul>
  • minhhango792

    Mar. 20, 2021
  • SHARATHCHANDRA173

    Oct. 18, 2017
  • kayal1927

    Jul. 19, 2015
  • DRAYUBAHMADKHAN

    Jun. 19, 2014

Vistas

Total de vistas

3.251

En Slideshare

0

De embebidos

0

Número de embebidos

1

Acciones

Descargas

146

Compartidos

0

Comentarios

0

Me gusta

4

×